Cover American Journal of Veterinary Research
American Journal of Veterinary Research
ISSN:
0002-9645
Publication Date:
01 Jun 2012

  • 1 Kurkjian CD, Ozer H. Leukopenia anemia and thrombocytopenia. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2008;2619–2621.

    • Search Google Scholar
    • Export Citation

  • 2 Thomas ED. Bone marrow transplantation: a review. Semin Hematol 1999; 36:95–103.

  • 3 Goldman JM, Horowitz MM. The international bone marrow transplant registry. Int J Hematol 2002; 76(suppl 1): 393–397.

  • 4 Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007; 39:577–588.

    • Search Google Scholar
    • Export Citation

  • 5 MacVittie TJ, Monroy RL, Patchen ML, et al. Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. Int J Radiat Biol 1990; 57:723–736.

    • Search Google Scholar
    • Export Citation

  • 6 Hasegawa T, Inomata T. Effect of recombinant human granulocyte colony stimulating factor on lymphocyte blastogenesis in healthy dogs. J Vet Med Sci 2000; 62:1205–1207.

    • Search Google Scholar
    • Export Citation

  • 7 Oguma K, Sano J, Kano R, et al. In vitro effect of recombinant human granulocyte colony-stimulating factor on canine neutrophil apoptosis. Vet Immunol Immunopathol 2005; 108:307–314.

    • Search Google Scholar
    • Export Citation

  • 8 Mei QL, Yang JY, Li YH, et al. Effects of granulocyte colony-stimulating factor on repair of injured canine arteries. Chin Med J (Engl) 2008; 121:143–146.

    • Search Google Scholar
    • Export Citation

  • 9 Henry CJ, Buss MS, Potter KA, et al. Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies. J Am Anim Hosp Assoc 1999; 35:236–239.

    • Search Google Scholar
    • Export Citation

  • 10 Lothrop CD Jr, Warren DJ, Souza LM, et al. Correction of canine cyclic hematopoiesis with recombinant human granulocyte colony-stimulating factor. Blood 1988; 72:1324–1328.

    • Search Google Scholar
    • Export Citation

  • 11 Pratt HL, Carroll RC, McClendon S, et al. Effects of recombinant granulocyte colony-stimulating factor treatment on hematopoietic cycles and cellular defects associated with canine cyclic hematopoiesis. Exp Hematol 1990; 18:1199–1203.

    • Search Google Scholar
    • Export Citation

  • 12 Rewerts JM, McCaw DL, Cohn LA, et al. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 1998; 213:991–992.

    • Search Google Scholar
    • Export Citation

  • 13 Mischke R, Barth T, Wohlsein P, et al. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis. Res Vet Sci 2001; 70:221–225.

    • Search Google Scholar
    • Export Citation

  • 14 Mishu L, Callahan G, Allebban Z, et al. Effects of recombinant canine granulocyte colony-stimulating factor on white blood cell production in clinically normal and neutropenic dogs. J Am Vet Med Assoc 1992; 200:1957–1964.

    • Search Google Scholar
    • Export Citation

  • 15 Frimberger AE, Moore AS, Rassnick KM, et al. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J Vet Intern Med 2006; 20:355–364.

    • Search Google Scholar
    • Export Citation

  • 16 Veterinary Co-operative Oncology Group. Veterinary Co-operative Oncology Group—common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004; 2:195–213.

    • Search Google Scholar
    • Export Citation

  • 17 Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002; 16:704–709.

    • Search Google Scholar
    • Export Citation

  • 18 Schuening FG, Storb R, Goehle S, et al. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood 1989; 74:1308–1313.

    • Search Google Scholar
    • Export Citation

  • 19 Akizuki S, Mizorogi F, Inoue T, et al. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects. Bone Marrow Transplant 2000; 26:939–946.

    • Search Google Scholar
    • Export Citation

  • 20 de la Rubia J, Martinez C, Solano C, et al. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Spanish Group of Allo-PBT. Bone Marrow Transplant 1999; 24:723–728.

    • Search Google Scholar
    • Export Citation

  • 21 Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111:1767–1772.

    • Search Google Scholar
    • Export Citation

  • 22 Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3:45–49.

    • Search Google Scholar
    • Export Citation

  • 23 Litam PP, Friedman HD & Loughran TP Jr. Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor. Ann Intern Med 1993; 118:954–955.

    • Search Google Scholar
    • Export Citation

  • 24 Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353:555.

    • Search Google Scholar
    • Export Citation

Advertisement

Editorial Type:
Oncology

Use of recombinant human granulocyte colony-stimulating factor prior to autologous bone marrow transplantation in dogs with lymphoma

Amy E. Lane BVSc1, Marisa J. Y. Chan BSc, BVMS2, and Kenneth M. Wyatt BSc, BVMS3
View More View Less
  • 1 Perth Veterinary Oncology, 305 Selby St N, Osborne Park, WA 6014, Australia.
  • | 2 Veterinary Medicine Specialists, 305 Selby St N, Osborne Park, WA 6014, Australia.
  • | 3 Perth Veterinary Oncology, 305 Selby St N, Osborne Park, WA 6014, Australia.
DOI:
https://doi.org/10.2460/ajvr.73.6.894
Volume/Issue:
Volume 73: Issue 6
Online Publication Date:
01 Jun 2012
Restricted access
Reprints and Permissions Purchase Article

Abstract

Objective—To retrospectively assess the safety and efficacy of recombinant human granulocyte colony-stimulating factor (G-CSF) used as part of autologous bone marrow transplantation in dogs with lymphoma.

Animals—21 dogs with lymphoma at any disease stage.

Procedures—Medical records of dogs with lymphoma that underwent intensified chemotherapy and received an autologous bone marrow transplant following owner administration of recombinant human G-CSF (5 μg/kg, SC, q 12 h) for 7 days between January 2007 and July 2009 were reviewed. Results of physical examinations and CBCs performed before and at intervals during a 24-month period after G-CSF treatment were assessed. The safety of recombinant human G-CSF administration was determined via assessment of both short-term (ie, during the 7-day G-CSF treatment period) and long-term adverse effects.

Results—None of the dogs developed any adverse effect attributable to the administration of recombinant human G-CSF during G-CSF administration or during follow-up periods of 1 month to 2 years (median follow-up period, 4 months). Among the 18 dogs for which CBC results were available for analysis, mean circulating neutrophil count significantly increased after administration of recombinant human G-CSF, compared with value before treatment.

Conclusions and Clinical Relevance—Results indicated that recombinant human G-CSF administered SC at a dosage of 5 μg/kg every 12 hours for 7 days appeared to be safe and effective when used in dogs with lymphoma that were undergoing autologous bone marrow transplant.

Contributor Notes

Address correspondence to Dr. Lane (amy@pvo.com.au).